Product Information
FLUTICASONE-SALMETEROL 113-14 is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $108.2789 per EA under NDC 00093360882. Its NADAC has been published 463 times since Nov 22, 2017.
FDA first approved this application on Jan 27, 2017.
Strength
113; 14 ug/1; ug/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093360882
Classification
Generic
Dosage Form
POWDER, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA208799FDA Approved
1/27/2017
On Market Since
4/28/2017
Pharmacological Classes
Price Statistics
The NADAC for FLUTICASONE-SALMETEROL 113-14 has been published 463 times since Nov 22, 2017, and over the history we have for it it has risen 26.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $108.2789 per EA |
|---|---|
| All-time high | $114.4698 (Jun 10, 2026) |
| All-time low | $80.9689 (Apr 21, 2021) |
| 52-week high | $114.4698 |
| 52-week low | $104.2930 |
| Median price | $91.1632 |
| Average price | $95.9476 |
| Largest weekly change | +17.1% (Apr 20, 2022) |
| Weeks tracked | 463 |
| Tracking since | Nov 22, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fluticasone Propionate and Salmeterol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FLUTICASONE-SALMETEROL 113-14?
The current National Average Drug Acquisition Cost (NADAC) for FLUTICASONE-SALMETEROL 113-14, manufactured by Teva Pharmaceuticals USA Inc., is $108.2789 per EA (NDC 00093360882), effective Sep 30, 2026.
How has the price of FLUTICASONE-SALMETEROL 113-14 changed over time?
Over the history we have for it, the NADAC for FLUTICASONE-SALMETEROL 113-14 has risen 26.6%. It has been tracked across 463 weekly CMS publications since Nov 22, 2017.
What are the highest and lowest recorded NADAC prices for FLUTICASONE-SALMETEROL 113-14?
Since Nov 22, 2017, the NADAC for FLUTICASONE-SALMETEROL 113-14 has ranged from a low of $80.9689 (Apr 21, 2021) to a high of $114.4698 (Jun 10, 2026), with a median of $91.1632 per EA.
Are there cheaper alternatives to FLUTICASONE-SALMETEROL 113-14?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as FLUTICASONE-SALMETEROL 113-14 in a comparable dosage form, but none are currently priced below it.
Who manufactures FLUTICASONE-SALMETEROL 113-14?
FLUTICASONE-SALMETEROL 113-14 (NDC 00093360882) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.